SC

Stephen Chambers

Managing Director at IndieBio NY & General Partner at SOSV

New York, New York

Invests in

Stages:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $2,000,000.00
  • Target Investment:

    $1,000,000.00

Work Experience

2020

  • Managing Director at IndieBio NY & General Partner at SOSV

    2020

  • Royal Society Entrepreneur in Residence

    2019 - 2021

    Helping commercialise world-leading research and address skills gaps in the emerging synthetic biology industry using real-world experience to help foster an entrepreneurial culture within universities and develop curricula to produce industry-ready graduates.

2016 - 2018

  • Co Founder

    2016 - 2018

    Accelerator for early stage companies looking to make an impact by solving the worlds most pressing problems. Biostart aims to support high-impact businesses targeting substantial markets with disruptive technology. Companies or teams with first class commercial acumen operating in any industry sector may apply. No age limits for the team or the company but any company applying must not have raised more than £500k equity funding. Annual competition is designed to commercialise the engineering of biology. The prize is £200k package (£100k equity free cash prize, six months free laboratory space, £25k consumables, £15k professional services). Non-dilutive, no equity taken. All entrants past the initial stage receive substantial mentoring and exposure to VC and business networks with a grand final event providing PR and networking opportunities.

2014 - 2018

  • CEO

    2014 - 2018

    Innovation and Knowledge Centre for Synthetic Biology, with the mission to accelerate and promote the commercial exploitation of synthetic biology research and technology in the UK. Author of the UK Synthetic Biology Start-up Survey.

2014 - 2018

  • Advisory Board Member

    2014 - 2018

    The establishment of the London DNA Foundry at Imperial College heralds a new chapter in the development of synthetic biology to meet new global challenges. The Foundry employs the latest technology to make the process of engineering biology easier, faster and scalable. The integration of advanced software, automation and analytics allows the rapid design, build and testing of engineered organisms.

2008 - 2013

  • Co Founder

    2008 - 2013

    Co-founded company producing novel antibodies & proteins for biomedical research.

  • Director of Gene Expression

    1990 - 2007

    A founding scientist and Director of Gene Expression at Vertex